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Abstract
Background: Telomeric 39 overhangs can fold into a four-stranded DNA structure termed G-quadruplex (G4), a formation
which inhibits telomerase. As telomerase activation is crucial for telomere maintenance in most cancer cells, several classes
of G4 ligands have been designed to directly disrupt telomeric structure.
Methods: We exposed brain tumor cells to the G4 ligand 3,11-difluoro-6,8,13-trimethyl-8H-quino[4,3,2-kl]acridinium
methosulfate (RHPS4) and investigated proliferation, cell cycle dynamics, telomere length, telomerase activity and activated
c-Myc levels.
Results: Although all cell lines tested were sensitive to RHPS4, PFSK-1 central nervous system primitive neuroectodermal
cells, DAOY medulloblastoma cells and U87 glioblastoma cells exhibited up to 30-fold increased sensitivity compared to
KNS42 glioblastoma, C6 glioma and Res196 ependymoma cells. An increased proportion of S-phase cells were observed in
medulloblastoma and high grade glioma cells whilst CNS PNET cells showed an increased proportion of G1-phase cells.
RHPS4-induced phenotypes were concomitant with telomerase inhibition, manifested in a telomere length-independent
manner and not associated with activated c-Myc levels. However, anti-proliferative effects were also observed in normal
neural/endothelial cells in vitro and ex vivo.
Conclusion: This study warrants in vivo validation of RHPS4 and alternative G4 ligands as potential anti-cancer agents for
brain tumors but highlights the consideration of dose-limiting tissue toxicities.
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Introduction
Human telomeres are repetitive TTAGGG sequences located
on the ends of chromosomes allowing cells to distinguish between
natural chromosome ends and double-strand DNA breaks [1,2].
The perpetual maintenance of telomeric DNA allows tumor cells
to possess unlimited replicative potential, one of the hallmarks of
cancer [3]. Activated telomerase maintains telomere length
homeostasis in ,85% of human cancers [4] justifying the
numerous anti-cancer strategies targeting components of the
telomerase holoenzyme [5,6,7,8,9,10,11,12]. However, such ap-
proaches require telomeres on one or more chromosome ends to
be critically eroded before any anti-cancer phenotype is observed
[13]. An alternate approach to cause both shortening of telomeres
and telomere uncapping is the use of G-quadruplex (G4) ligands.
As telomerase requires the 39 telomeric end to be in a single-
stranded configuration, sequestering of the telomere in a four-
stranded structure by small molecules that can compete with
telomere-associated proteins, inhibits the binding of telomerase to
telomere ends. The resulting loss of telomere maintenance
precedes activation of a DNA damage response and growth arrest
[14]. Many chemical classes of G4 ligands have been described
which reduce the growth of various cancer cell lines in vitro
[15,16,17,18,19] and exhibited antitumor activity in vivo [20,21].
However, direct evidence of G4-mediated telomerase inhibition as
a proximal event is minimal due to a lack of reliable in vitro
telomerase assays. The claim of telomerase inhibition in many
studies could be erroneous due to the inhibition of Taq polymerase
by G4 ligands [17,22]. More recent re-evaluations of telomerase
inhibition by G4 ligands support this claim [22,23,24]. Although
any G4 ligand that can inhibit the replication of TTAGGGn by
Taq polymerase will likely also inhibit telomerase, IC50 values
determined from such a telomerase activity assay are likely to be
incorrect. There is therefore a need for more accurate telomerase
detection methods that may circumvent the requirement of Taq
polymerases. In addition to preventing telomerase access to the
telomere substrate, G4 ligands can exert anti-cancer effects as a
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result of uncapped telomeres due to the loss of binding of telomeric
proteins such as POT1, TRF 1 and TRF2. G4 ligand induced
effects can further be potentiated through stabilization of G-
quadruplexes at non-telomeric G-rich loci, particularly promoter
regions of oncogenes such as c-Myc [25,26,27,28].
Pentacyclic 3,11-difluoro-6,8,13-trimethyl-8H-quino[4,3,2-kl]a-
cridinium methosulfate (RHPS4) was part of a series of acridinium
salts that were synthesized at the University of Nottingham
(Nottingham, UK) which showed preference for binding to and
stabilizing, G4 DNA isoforms over DNA duplexes [29,30,31,32].
Treatment of various cancer cell lines and tumor xenografts
revealed that RHPS4 was a potent telomerase inhibitor at
submicromolar concentrations, caused irreversible proliferation
arrest after long-term culture at non-cytotoxic concentrations and
exhibited antitumoral activity in vivo [17,29,33]. However when
used at higher doses, RHPS4 triggered short-term apoptosis/
senescence in human melanoma cells [17] and a potent DNA
damage response at the telomeres of transformed human
fibroblasts, melanoma cells and uterine cancer cells, characterized
by the appearance of the phosphorylated DNA damage response
factors c-H2AX, RAD17 and 53BPI. This phenotype however,
was antagonized by overexpression of the telomere binding
proteins POT1 and TRF1 [14,34].
Here we investigated G4 ligand-mediated anti-tumor effects on
malignant childhood and adult brain cancer cells in vitro using the
pentacyclic acridine RHPS4 as proof-of-concept and further
assessed toxicity of RHPS4 in vitro and in functional ex vivo assays.
Materials and Methods
Cell Lines
PFSK-1 (pediatric central nervous system primitive neuroecto-
dermal tumor (CNS PNET)), DAOY (pediatric medulloblastoma),
C6 (rat glioma) and U87 (adult glioblastoma) cell lines were
obtained from American Type Culture Collection (ATCC,
Manassas, VA, USA). The GB-1 line (reclassified as pediatric
grade III mixed glioneuronal), was derived at the University of
Birmingham, UK and previously reported by us [35]. KNS42
(pediatric glioblastoma) was a kind gift from Dr. Chris Jones at the
Institute of Cancer Research, London and previously isolated and
characterized [36]. Res196 (pediatric ependymoma) was a kind
gift from Dr. Michael Bobola at Seattle Children’s Hospital
Research Institute [37]. C17.2 neural progenitor cells isolated
from neonatal mouse cerebellar cortex and immortalized with v-
Myc have been previously described [38]. Human brain micro-
vascular brain endothelial cells (HBMEC) were a kind gift from
Dr. Naveed Khan, University of Nottingham [39].
Cell Culture and Drug Preparation
Cells were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) (Sigma, UK) (DAOY, C6, GB-1, U87 and C17.2),
RPMI-1640 (Sigma, UK) (PFSK-1) or DMEM/F12 (Sigma, UK)
(KNS42 and Res196), supplemented with 10% fetal bovine serum
(FBS) (or 10% FBS/5% horse serum (C17.2)) (PAA Labs, UK).
HBMEC cells were cultured in RPMI-1640 media as previously
described but supplemented with 20% fetal bovine serum and 1%
MEM vitamins (Invitrogen, UK).
Proliferation Assay and Drug Exposure
Cells were seeded at a density of 56104 cells per well of a 24-
well plate, 24 hours prior to 0.5–50.0 mM RHPS4 exposure for 72
hours. Alamar Blue assay (Invitrogen, UK) was conducted
according to the manufacturer guidelines and fluorescence
emission measured at 585 nm using a plate reader (Tecan,
Switzerland). Percentage viability was calculated related to vehicle-
only treated controls. Qualitative images of RHPS4-treated brain
tumor cells were taken using a standard light microscope (Leica,
UK). IC50 values refer to the concentration at which the tumor
population viability is 50% that of the corresponding untreated
tumor population.
Cell Cycle Analyses
RHPS4-treated cells were fixed with cold ethanol, washed with
cold PBS (with 0.1% BSA, 0.1% Tween) and stained with 20 mg
propidium iodide for 20 minutes in the dark and at room
temperature. Cell cycle analysis was conducted using a Coulter
FC500 flow cytometer and analyzed using WinMDI2.8 and
Cylchred software. Four independent experiments were conducted
for all samples with the mean percentage of each fraction
presented.
Telomere Restriction Fragment (TRF) Length Assay
The TRF assay determines mean telomere length in a
population of cells or in tissue. Mean telomere length was
determined using the TeloTAGGG kit according to the manu-
facturer guidelines (Roche, Burgess Hill, UK). Briefly, 3 mg
genomic DNA per sample was digested using a frequent cutter
restriction enzyme mix, leaving undigested telomeric DNA, which
was resolved on 0.8% agarose gel. Blots were transferred to a
nylon membrane, probed with a telomere-specific probe and
exposed to film. The average TRF length was determined by
comparing telomere smear and intensity signals relative to a
molecular weight standard using ImageQuant version 5.1 software
(GE Healthcare, Buckinghamshire, UK).
Telomere Repeat Amplification Protocol (TRAP) Assay
Telomerase activity was analyzed using the TRAPeze telome-
rase detection kit (Millipore, Hertfordshire, UK). Standard TRAP
assays were conducted using 100–500 ng protein according to the
manufacturer guidelines and visualized with a Fujifilm FLA-2000
phosphoimager (Amersham Biosciences, Buckinghamshire, UK).
For pre-extension modified TRAP assays, RHPS4 was added to
cell-free lysates after a 5 minutes telomere extension step (to
generate a telomere product of at least four hexameric repeats) but
prior to an additional 25 minutes telomere extension. For post-
extension modified TRAP assays, RHPS4 was added to cell-free
lysates immediately upon completion of telomere extension. To
eliminate RHPS4 prior to the PCR stage, telomere extended
products were first ethanol precipitated after phenol/chloroform.
Quantitative TRAP assays were conducted using the TRAPeze
XL telomerase detection kit according to manufacturer guidelines
(Millipore, Hertfordshire, UK). The TRAP assay was conducted
three times using independent RHPS4-treated TS oligonucleo-
tides.
c-Myc Transcription Factor Assay
Activation of c-Myc was analyzed using the TransAMTM c-Myc
transcription factor assay kit (Active Motif, UK). TransAMH Kits
are sensitive, non-radioactive transcription factor ELISA kits that
facilitate the study of transcription factor activation in mammalian
tissue and cell extracts. Nuclear extracts were isolated from brain
tumor cells treated with RHPS4 for 72 hours using the Nuclear
Extract kit (Active Motif, UK) and 2 mg of nuclear extract used in
the c-Myc transcription factor assay according to the manufacturer
guidelines. Jurkat nuclear extract was used as a positive control.
Three independently-derived nuclear extracts were used for each
sample.
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c-Myc Quantitative Reverse-transcriptase PCR
Total RNA was extracted from RHPS$-treated cell pellets using
the mirVanaTM miRNA Isolation kit (Applied Biosystems,
Carlsbad, CA, USA). cDNA synthesis was carried out by
incubating 500 ng RNA with 200 U reverse transcriptase
(Fermentas, St. Leon-Rot, Germany) at 42uC for 1 hour. PCR
reactions were carried out using 1Q Custom SYBR Green
Supermix (Bio-Rad, Hercules, CA, USA) and 100 nM forward
and reverse primers (human c-Myc forward primer ACT-
CAGTCTGGGTGGAAGGT, reverse primer CGTATACTTG-
GAGAGCGCGT; rat c-Myc forward primer CTGTACGCC-
CAAACGCAAAA, reverse primer
TTAGTCACCGCAGGTGGAAC). The CFX96 real time PCR
machine (Bio-Rad) was used. PCR conditions were 95uC for 10
minutes followed by 40 cycles of 95uC for 30 seconds, 60uC for 1
minute and 72uC for 1 minute. Data was normalized using
GAPDH (forward primer CGCTCTCCAGAACATCATCC,
reverse primer GGAGATTCAGTGTGGTGG).
Ependymal Cell Culture and Cilia Function ex vivo
Primary ependymal cells were grown as described previously in
[40]. Ciliated adherent ependymal colonies were cultured with or
without RHPS4 (3 mM or 30 mM). To determine cilia beat
frequency (CBF) and cilia tip distance travelled, cultured cells were
placed in a humidified incubation chamber (37uC) and observed
using an inverted microscope (TxU, Nikon, UK). Beating cilia
were recorded using a digital high-speed video camera (X4, Lake
Image Systems, UK) at a rate of 500 frames per second. Each
time-point represents the measurement of CBF and tip distance at
5 regions of interest (ROI) from 3 ciliated cells (563=15 readings
per time point). The data are from four separate primary cultures
from four rat brains. Calculation of CBF (Hz): 500 (no. frames per
second)/5 (frames elapsed for five ciliary beat cycles)65 (conver-
sion per beat cycle). The captured video sequences were played
back at a slow rate which allowed determination of the distance
travelled by cilia tips within the power stroke of the beat cycle.
Statistical Analyses
SPSSv16 was used for performing all statistical analyses.
Independent-sample t-tests with 95% confidence intervals were
used to compare the viability of RHPS4-treated versus untreated
cells and to assess c-Myc activation levels with or without RHPS4
exposure. Data is presented as the average relative fluorescence
units or absorbance respectively, of three independent experiments
with error bars indicating standard error of the mean values.
Correlation between results from the Alamar Blue proliferation
assay and TRF length assays was determined by a Pearson’s
correlation test. P-values less than or equal to 0.05 were deemed
statistically significant throughout. One-way ANOVA analyses
was conducted to establish the variance between untreated and
drug-treated samples in the ciliated ependymal cell toxicity assay
and the Tukey HSD sub-group test was used to establish
significant differences between groups at specific time intervals.
One-way ANOVA analyses was used to determine significance
between drug-treated and untreated samples with respect to each
cell cycle fraction, where a p-value of less than or equal to 0.05 was
deemed to represent a significant increase or decrease in the
respective fraction.
Results
Acute Exposure to RHPS4 Results in Dose-dependent
Inhibition of Growth in Brain Tumor Cells
CNS PNET, medulloblastoma, high grade glioma and ependy-
moma cells were treated with RHPS4 for an acute 72 hour period
at an initial concentration range of 0.5–5.0 mM, followed by a
concentration range of 1.0–50.0 mM for relatively less sensitive cell
lines. PFSK-1, DAOY, U87 and Res196 cells display a significant
dose-dependent viability loss at 0.5–5.0 mM RHPS4 with half
maximal inhibitory concentration (IC50) values of 2.7, 2.2, 1.1 and
1.6 mM respectively (p#0.05 for each drug concentration versus
untreated). Approximately 2–40% of viable cells remained after
the highest drug dose (5 mM) after 72 hours treatment (Figure 1A,
C and E). Within this concentration range, KNS42, C6 and GB-1
cells are resistant to RHPS4 (Figure 1D and F, G). However at
concentrations .10.0 mM, KNS42, C6 and GB-1 display a
significant dose-dependent viability loss with IC50 values of 15.0,
26.0 and 32.0 mM respectively (p#0.05 for each drug concentra-
tion versus untreated). Approximately 30–50% of viable cells
remained after the highest drug dose after 72 hours treatment
(Figure 1D and H, I). Light microscopy of RHPS4-treated PFSK-
1, DAOY, C6 and GB-1 cells, qualitatively shows a dose-
dependent viability loss with marked growth arrest at concentra-
tions above 2.0 mM RHPS4 for PFSK-1 and DAOY cells and
20.0 mM RHPS4 for C6 and GB-1 cells after 72 hours treatment
(Figure 1J, M). Non-acute concentrations of RHPS4 however (10-
fold below that which resulted in an IC50 value in the acute
regime), had no obvious effect on population doubling time in
PFSK-1 and C6 cells after 23 and 36 days respectively, chosen as
representative cell lines for differential RHPS4 sensitivity (Figure
S1). These results provide proof-of-concept that several brain
tumor cell types are dose-responsive to the RHPS4 G4 ligand
in vitro with PFSK-1, DAOY, U87 and Res196 cells exhibiting 10
to30 fold greater sensitivity than KNS42, C6 and GB-1 cells.
Further molecular and cellular characterizations were conducted
using cell lines representative of the observed difference in RHPS4
sensitivity, with PFSK-1/DAOY representing relatively greater
sensitivity to RHPS4 and C6/GB-1 representing relatively
reduced sensitivity to RHPS4.
Alterations in Cell Cycle Dynamics upon RHPS4 Exposure
in vitro are Cell Line Dependent
Based upon IC50 values, cell lines were treated with appropriate
RHPS4 concentrations for 72 hours and cell cycle profiles
analyzed. PFSK-1 cells showed a significant (F2,9 = 6.97,
p = 0.015) increase in the proportion of cells in G1-phase which
was dose-dependent, with a moderate but significant (F2,9 = 4.752,
p = 0.039) increase of cells in the sub-G0/1 stage at the higher
RHPS4 concentration (5 mM). In contrast DAOY, C6 and GB-1
showed a broadly dose-dependent significant (F2,9 = 10.35,
p = 0.005; F2,9 = 4.26, p = 0.05; and F2,9 = 6.24, p = 0.02 respec-
tively) increase in the proportion of cells in S-phase, with a slight
accompanying increase of DAOY sub-G0/1 cells observed at the
higher RHPS4 concentration (5 mM), although the latter did not
reach statistical significance (Figure 2). Although an increase in the
G1/S fraction suggests impaired proliferation of brain tumor cells
relative to untreated cells, drug-treated cells were observed to
recover and proliferate after withdrawal of RHPS4, presumably
due to the presence of RHPS-resistant clones (within the drug
concentrations used in these experiments) (Figure S2).
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RHPS4-mediated Short-term Anti-cancer Effects in vitro
and Association with Telomere Length
As folding of the single-strand telomeric substrate into a four-
stranded quadruplex structure inhibits the catalytic activity of
telomerase [41], it is plausible that G4 stabilization results in
telomerase inhibition proceeded by telomere shortening as a
consequence. In this scenario, growth arrest is predicted to be
directly related to initial mean telomere length. Therefore we
hypothesized that the 10 to15 fold decreased sensitivity of C6 and
GB-1 glioma cells treated with RHPS4 (compared to PFSK-1 and
DAOY cells) is inversely proportional to mean telomere length.
PFSK-1 and DAOY exhibited mean TRF lengths of 3.8 kb and
7.8 kb, respectively, whilst C6 and GB-1 glioma lines exhibited
mean TRF lengths of 7.5 kb and 3.9 kb respectively (Figure 3A).
Although no significant correlation was evident between 72 hour
RHPS4 sensitivity and mean telomere length using representative
tumor lines (Pearson’s coefficient r =20.141, p,0.86), it is
plausible that correlation with telomere length would be observed
Figure 1. Acute RHPS4 exposure inhibits proliferation of high grade brain tumor cells in vitro. Proliferation of tumor cells was impaired in
malignant brain tumor cells after acute 72 hours exposure to RHPS4. (A–C) PFSK-1, DAOY, U87 and (E) Res196 cells exhibited IC50 values of 2.7, 2.2, 1.1,
and 1.6 mM respectively when 0.5–5.0 mM RHPS4 was used, representing a significant inhibition of cell proliferation (p#0.05 for each drug
concentration versus untreated). (D, F–G) Within this concentration range, KNS42, C6 and GB-1 cells were resistant to RHPS4. (H–I) At higher
concentrations of RHPS4 exposure C6 and GB-1 cells exhibited IC50 values of 26 mM and 32 mM respectively, representing a significant inhibition of
cell proliferation (p#0.05 for each drug concentration versus untreated). Error bars indicate standard error from three independent experiments. (J–
M) Light microscopy of PFSK-1, DAOY, C6 and GB-1 cells showing a marked reduction in cellular density after RHPS4 exposure. Magnifications, x20;
Scale bar = 25 mm.
doi:10.1371/journal.pone.0086187.g001
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when considering RHPS4 sensitivities after .72 hour exposure
within these cell lines.
RHPS4 Inhibits Taq Polymerase in Cell-free Telomerase
Activity Assays
To assess the effects of G4 stabilization directly at the telomere
substrate, we introduced RHPS4 directly into cell-free TRAP
assays using drug-treated protein/RNA lysates in order to
discriminate whether RHPS4-mediated inhibition of telomerase
excludes inhibition of Taq polymerase by this G4 ligand. A 5
minute telomere extension period using a telomere oligonucleotide
substrate, permitted the synthesis of the minimum four hexameric
TTAGGG telomere repeats required for G4 ligands to stabilize a
four-stranded DNA structure (Figure 3B, C), prior to an additional
25 minutes telomere extension [23]. PFSK-1 and DAOY showed
low levels of telomerase activity at low RHPS4 concentrations and
complete absence of telomerase activity at high RHPS4 concen-
trations. Similarly C6 and GB-1 showed complete absence of
telomerase activity at both RHPS4 concentrations analyzed
(Figure 3D). However when RHPS4 was introduced to cell-free
lysates immediately upon completion of 30 minutes telomere
elongation but prior to the PCR amplification stage of the TRAP
assay, telomerase activity was also absent and at all concentrations
of drug analyzed (Figure 3E). Our results strongly indicate that
RHPS4 inhibits Taq polymerase during the PCR stage of the
TRAP assay and therefore RHPS4-mediated inhibition of
telomerase activity cannot be determined when the ligand is
introduced either prior to or immediately after, telomere
extension.
RHPS4 Inhibits Telomerase Activity in TRAP Assays Using
Purified Telomere Products
Prior to PCR amplification stage, DNA extraction of elongated
telomere fragments via ethanol precipitation was conducted to
eliminate RHPS4 from telomere extension products. High
telomerase activity was observed in all untreated cell lines after
extracted telomere extended PCR products were resolved on
acrylamide gels (Figure 4A). A drug concentration range in
accordance to our previously established IC50 values (Figure 1) was
used for the direct introduction of RHPS4 into the cell-free TRAP
assay prior to purification of telomere extension products (1.6–
12.8 mM for PFSK-1/DAOY; 6.4–51.2 mM for C6/GB-1).
Substantial telomerase inhibition was observed in PFSK-1 cells
with only very weak telomerase activity at each RHPS4
concentration (Figure 4B). Complete telomerase inhibition was
observed in DAOY, C6 and GB-1 cells and at each drug
concentration (Figure 4C, D, E). These results indicate that the
presence of RHPS4 in a mixture containing cell-free brain tumor
lysates and a telomere substrate oligonucleotide, results in a clear
abrogation of telomerase activity in vitro. This result suggests one
plausible mechanism through which RHPS4 may exert anti-
proliferative effects in brain tumor cells utilized in this study. We
cannot however exclude the possibility of some RHPS4 molecules
remaining bound to the telomere substrate after ethanol precip-
itation, thereby impeding hybridization with telomere-specific
primers and resulting in an overestimation of telomerase
inhibition.
RHPS4 Sensitivity is not Associated with Activation of c-
Myc
To investigate whether other G-rich genomic sequences are
susceptible to RHPS4, activated c-Myc protein levels were
assessed upon exposure to RHPS4 using the TransAMTM c-Myc
assay. The c-Myc protein was chosen on the basis that
deregulation of c-Myc has been implicated in the origin of diverse
human cancers and the c-Myc gene contains a G-rich promoter
sequence [42,43]. Jurkat tumor cell nuclear extracts show
activation of c-Myc proportional to concentration of extract
analyzed verifying the sensitivity of the TransAMTM c-Myc assay.
A wild-type consensus oligonucleotide competitively binds to c-
Myc, whereas a mutant oligonucleotide has no distinct effect,
collectively demonstrating the specificity of the assay (Figure 5A).
PFSK-1 and C6 cells were selected for representative analyses as
these lines differed in RHPS4 sensitivity by ,10-fold (Figure 1A
and C). PFSK-1 cells treated with RHPS4 did not show a
significant reduction in c-Myc activation at all drug concentrations
analyzed relative to untreated vehicle-only controls (Figure 5B)
(p#0.05). Similarly, c-Myc activation levels at each RHPS4
concentration (1.0–50.0 mM) were comparable to untreated
controls in C6 cells (Figure 5C) (p#0.76). In both PFKS-1 and
C6 cells, specificity for c-Myc expression was confirmed by
addition of the wild-type oligonucleotide competitor during the
assay; c-Myc expression levels were significantly reduced when this
inhibitor was added to untreated cells (Figure 5B, C; p#0.02). In
addition, no reduction in c-Myc gene expression levels as
determined by quantitative reverse transcriptase PCR, were
observed in either PFSK-1 or C6 RHPS4-treated cells relative
to untreated cells (Figure 5D, E). These results collectively suggest
that RHPS4 sensitivity is not directly associated with downregu-
lated c-Myc levels in brain tumor cells in vitro.
Figure 2. Acute RHPS4 exposure alters cell cycle dynamics of
brain tumor cells in vitro. PFSK-1 cells exhibited a dose-dependent
increase in the proportion of cells in G1-phase. In contrast DAOY, C6
and GB-1 cells exhibited a dose-dependent increase in the proportion
of cells in S-phase. PFSK-1 further shows a moderate accompanying
increase of sub-G0/1 cells at the higher RHPS4 concentration (5 mM).
Percentages are the mean from three independent experiments.
Asterisk denotes a significant difference relative to untreated cells.
doi:10.1371/journal.pone.0086187.g002
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Normal Neural and Endothelial Cells are Sensitive to
RHPS4 Exposure in vitro and ex vivo
To assess potential adverse cellular toxicity upon RHPS4
treatment, mouse cerebellar progenitor cells and human brain
endothelial cells were analyzed for viability after an acute 3-day
exposure to RHPS4. Both cell lines were sensitive to RHPS4
under these conditions, with an IC50 of 15 mM and 5 mM
respectively (Figure 6A, B). To better elucidate what effects
RHPS4 may have on the functional capacity of neural cells, we
utilized an ependymal culture system ex vivo as a measure of neural
cell function based on ependymal cilia. Primary rat ependymal
cultures were assessed for functional impairment of ependymal
CBF and cilia tip distance after 3 mM or 30 mM RHPS4 exposure
relative to untreated cultures. A significant difference in CBF was
observed across the entire cohort at 1 hour, 24 hours and 30 hours
post-treatment (p#0.0001). By 30 hours post-treatment, both the
3 mM and 30 mM groups showed a significant reduction in CBF
compared to the untreated group (p#0.01) (Figure 6C). Cilia tip
distance was also measured in ependymal cultures and similarly
showed a significant difference across the entire cohort at 1 hour,
24 hours and 30 hours post-treatment (p#0.0001). By 24 hours
post-treatment, both the 3 mM and 30 mM group showed a
significant reduction in cilia tip distance compared to the
untreated group (p#0.01). (Figure 6D). These experiments
collectively show that neural and endothelial cells display dose-
dependent sensitivity to RHPS4.
Discussion
Here we present a rationale for using G4 ligands for the
treatment of certain childhood and adult brain tumors using
RHPS4 as proof-of-concept of this class of anti-tumor agent and
mechanism of G4 ligand action.
Strategies to inhibit telomerase have typically focused on
targeting the human telomerase reverse transcriptase (hTERT)
and human telomerase RNA (hTR) components of the telomerase
enzyme [44,45,46,47]. Anti-cancer phenotypes resulting from this
approach are observed when one or more telomeres become
critically short due to an absence of telomerase-mediated telomere
maintenance, manifesting in senescence or apoptosis. As a
telomere length-dependent lag may impact on the time to growth
arrest in malignant cells, direct disruption of telomere structure
whereby proliferation is arrested rapidly is an attractive strategy.
Our result is consistent with previous studies that failed to observe
telomere reduction in tumor cells after RHPS4 exposure [17,29].
However our data do not exclude the possibility that non-acute
nanomolar doses of RHPS4 or .72 hour drug exposure may
induce gradual telomere shortening associated ultimately with a
senescent phenotype. In particular, G4 ligand treatment of
telomerase-positive glioma cell lines resulted in telomere instabil-
ity, cell cycle alterations and apoptosis in a telomere length-
independent manner, with IC50 values similar to those presented
in our data [27]. However, our data does not exclude the
Figure 3. Telomere length measurement and RHPS4-mediated inhibition of Taq polymerase in vitro. (A) Mean TRF lengths for PFSK-1/
DAOY cells (3.8 kb/7.8 kb) and C6/GB-1 (7.5 kb/3.9 kb) cells were determined prior to RHPS4 exposure. (B) Quantitative TRAP assay showing
telomerase-mediated telomere extension after 30 minutes (standard TRAP assay) or 5 minutes extension time in non-drug exposed cells. (C) PCR gel
showing telomere extension products after 5 minutes extension time in non-drug exposed cells. 1, no lysate control; 2–5, PFSK-1, DAOY, C6 and GB-1.
(D) PFSK-1 and DAOY showed low levels of telomerase activity at low RHPS4 concentrations and complete absence of activity at high RHPS4
concentrations, when RHPS4 was added pre-telomere extension. C6 and GB-1 showed complete absence of telomerase activity at both RHPS4
concentrations analyzed. (E) Telomerase activity was absent in all cell lines and at both RHPS4 concentrations when RHPS4 was added post-telomere
extension. CHAPS, CHAPS buffer only no lysate control; IC, internal control 61-bp telomere substrate oligonucleotide.
doi:10.1371/journal.pone.0086187.g003
G4 Ligand Impairs Growth of Brain Tumor Cells
PLOS ONE | www.plosone.org 6 January 2014 | Volume 9 | Issue 1 | e86187
possibility that telomerase inhibition at a subset of critically short
telomeres may be necessary for RHPS4-mediated anti-prolifera-
tive effects as we have assessed mean telomere length within each
tumor cell line.
RHPS4-treated brain tumor cells analyzed in this study exhibit
an increase in the proportion of cycling cells in G1 or S phase,
suggesting growth arrest in either phase. The very low sub-G0/1
fraction in drug-treated cells indicates that only few cells display a
late-stage cell death phenotype, consistent with our direct
qualitative visualization of cells. This suggests that RHPS4 in this
context primarily acts to inhibit growth, at least within the time-
frame and drug concentrations of the experiments used here.
Although the Alamar Blue assay does not discriminate between
proliferating cells and growth arrested but viable cells, the lack of a
Figure 4. Acute RHPS4 exposure is associated with telomerase inhibition in brain tumor cells in vitro. (A) TRAP assay using ethanol-
precipitated telomere extended DNA products after 30 minutes extension in non-drug treated brain tumor cells. High levels of telomerase activity are
observed in each cell line. (B–D) TRAP assays in RHPS4-treated brain tumor lysates reveals complete telomerase inhibition in all cell lines at each drug
concentration. 0.1 mg of total protein lysate was loaded per well in each TRAP assay. CHAPS, CHAPS buffer only no lysate control; TS, telomere substrate
internal control 61-bp oligonucleotide.
doi:10.1371/journal.pone.0086187.g004
G4 Ligand Impairs Growth of Brain Tumor Cells
PLOS ONE | www.plosone.org 7 January 2014 | Volume 9 | Issue 1 | e86187
marked sub-G0/1 population as determined by cell cycle analyses
and lack of directly observable dead cells in culture flasks, indicates
that RHPS4-mediated anti-cancer effects are due to impaired
tumor cell growth. However, our data indicates that resistant
tumor cells that survive treatment are able to proliferate and re-
populate the tumor population in vitro.
Phenomena induced by acute exposure to G4 ligands are likely
due to activation of DNA damage pathways and subsequent
genomic catastrophe. Prolonged stabilization of a quadruplex
structure may prevent protection of POT1 and TRF1 proteins
from binding to 39 telomeric overhangs and thereby sheltering
chromosomal ends from DNA damage surveillance [25]. The
,10-fold difference in RHPS4 sensitivity between PFSK-1/
DAOY embryonal cells and C6/GB-1 glioma cells is plausibly
due to competitive binding of RHPS4 and POT1 to the 39
overhang. In this scenario, the less sensitive C6 and GB-1 cells
may exhibit higher levels of POT-1 protein at telomeres. In
support of this hypothesis, potent DNA damage response at
telomeres upon RHPS4 exposure is antagonized by overexpres-
sion of POT1 or TRF2 [14,28]. Such findings suggest that G4
ligands can induce relatively rapid telomere uncapping and may
explain why reductions in telomere length are not always observed
in cells exposed to these compounds. As a corollary, POT1 or
TRF1 displacement from telomeres may serve as appropriate
biomarkers of G4 ligand target modulation in clinical trials. It is
important to note however that whether RHPS4 potency
associates with telomere length may be dependent on the tumor
cell type under investigation. A panel of 36 xenograft cell lines
Figure 5. c-Myc activation is not associated with degree of RHPS4 sensitivity. (A) c-Myc transcription factor assay. Jurkat cell nuclear
extracts show activation and specificity of c-Myc proportional to concentration of extract analyzed and in the presence of wild-type or mutant
competitor. (B–C) No significant difference in c-Myc activation was observed between untreated PFSK-1 or C6 cells and RHPS4-treated cells. Asterisk
denotes significant reduction in c-Myc levels when either PFSK-1 or C6 untreated cells were exposed to a wild-type oligonucleotide competitor
(p#0.05). (D–E) c-Myc quantitative reverse transcriptase PCR. No difference in PFSK-1 or C6 c-Myc gene expression was observed between
representative RHPS4-treated cells and untreated cells.
doi:10.1371/journal.pone.0086187.g005
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derived from several human tumor types showed a strong
correlation between telomere length and RHPS4 sensitivity [48].
The careful consideration of non-telomeric routes to toxicity was
highlighted in a recent study describing light-dependent oxidative
stress response, rather than G-quadruplex binding, as the major
route to toxicity [49].
Several previous reports have claimed direct evidence of
telomerase inhibition upon exposure of tumor cells to various
G4 ligands [17]. These cell-free telomerase activity studies
incubated ligands with protein/RNA lysates prior to telomere
extension and PCR amplification. As several G4 ligands have
more recently been shown to inhibit Taq polymerase during the
PCR process, these studies may erroneously report telomerase
inhibition [22,23,24]. In our study, telomere extended products
were first precipitated after G4 ligands were incubated with
protein/RNA lysates in addition to a telomere oligonucleotide
substrate, prior to PCR amplification. Therefore the absence of
telomere products observed in TRAP gels indicates true RHPS4-
induced telomerase inhibition. Complete abrogation of telomerase
activity in a cell-free assay was observed at RHPS4 concentrations
below that required for 50% growth inhibition in drug-treated cell
cultures. However, although our findings demonstrate RHPS4-
mediated inhibition of telomerase activity via stabilization of a
telomere oligonucleotide, direct evidence of telomerase inhibition
in a cellular context is required. It will be intriguing to test the
effects of RHPS4 against brain tumor stem-like populations that
exhibit high levels of telomerase activity and long telomeres
relative to the tumor population as a whole. Indeed the G4 ligand
Telomestatin impairs glioma stem cell survival and growth
through disruption of the telomere G-quadruplex and inhibition
of the c-Myb proto-oncogene [26]. As c-Myc is de-regulated in
several tumors and can contribute to the transcriptional activation
of the hTERT gene in tumor cells, RHPS4-mediated stabilization
at the c-Myc promoter may exacerbate telomerase inhibition
effects in the tumor cell due to down-regulation of hTERT
[50,51]. Additionally, lack of c-Myc amplification in supratentorial
PNET tumor tissue and in the PFSK-1 cell line may be a
contributing factor to sensitivity to RHPS4 as patients with other
PNET tumors which exhibit overexpression or amplification of c-
Myc, have an extremely poor prognosis with poor response to
chemotherapy [52,53]. The baseline c-Myc protein level as
determined by the Trans-AM assay is significantly higher in
PFSK-1 cells (p#0.3), but C6 c-Myc expression level is as high as
92% that of PFSK-1 c-Myc levels. Therefore basal c-Myc levels
are unlikely to contribute to the differences in possible G4
stabilization at the c-Myc promoter in these cells. However our
observation that activated c-Myc levels are not significantly down-
regulated in either RHPS4-treated PFSK-1 or C6 cells, suggests
that RHPS4-mediated effects in this context are not due to
stabilization of G-rich elements at the c-Myc promoter. This is
contrasted by studies demonstrating that the G-rich region
upstream of the P1 promoter of the c-Myc gene controls ,90%
of its transcriptional regulation and that G4 ligands can stabilize
Figure 6. RHPS4 sensitivity in normal neural and endothelial cells in vitro and ex vivo. (A) C17.2 cerebellar progenitor cells and (B) HBMEC
endothelial cells are sensitive to RHPS4 with an IC50 of 15 mM and 5 mM respectively. (C) Primary rat ependymal ex vivo cultures exhibited functional
impairment of ependymal CBF after 3 mM or 30 mM RHPS4 exposure (p#0.01). (D) A significant reduction in cilia tip distance was observed after
either 3 mM or 30 mM RHPS4 exposure (p#0.01). Error bars represent standard error of the mean from four separate rat brains/experiments.
doi:10.1371/journal.pone.0086187.g006
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the c-Myc promoter quadruplex and disable c-Myc in childhood
medulloblastoma cells in vitro [54,55,56].
As RHPS4 exerted dose-dependent viability loss in normal
neural/endothelial cells and impaired neural function in ciliated
ependymal cells, our findings highlight the need for rigorous
consideration of dose-limiting tissue toxicities when using G4
ligands for the targeting of cancer cells and/or G4 ligands with
greater specificity for the binding to telomere substrates. Certain
tumor types may be more amenable to this mode of therapy,
where anti-cancer effects occur within a therapeutic window that
results in acceptable toxicities to healthy tissue. Moreover non-
acute repeated dosing of G4 ligands may be a more feasible
strategy in the clinic. As several G4 ligands have been extensively
studied in laboratory-based and pre-clinical studies, it will be
important to test a broad range of these ligands specifically for
brain tumor efficacy and neural toxicities using in vitro and in vivo
strategies, prior to consideration in early phase patient trials.
Conclusions
To our knowledge, this is the first report of RHPS4-induced
viability loss in brain tumor cells. We have evaluated the poly-
pharmacophoric nature of RHPS4 and shown that impairment of
tumor cell viability is a proximal event and likely associated with
G1/S phase arrest. We further suggest that RHPS4 sensitivity is
not attributable to G-rich c-Myc promoter G-quadruplex but we
cannot rule out stabilization at other non-telomeric loci.However,
our data suggests the presence of RHPS4-resistant cells and direct
evidence of telomerase inhibition in a cellular context is required.
Our findings highlight confounds that need to be addressed for the
consideration of G4 ligands as potential pharmacologic agents for
the treatment of childhood and adult brain tumors, whilst
highlighting the parallel requirement for careful evaluation of
unwanted toxicities prior to clinical trial consideration.
Supporting Information
Figure S1 No alterations in growth rate following non-
acute RHPS4 exposure in PFSK-1 and C6 brain tumor
cells. (A) PFSK-1 cells were exposed to 0.2 mM RHPS4 for
23 days and (B) C6 cells were exposed to 2 mM RHPS4 for
36 days. No marked alteration in population doubling rate was
observed for either cell line treated with RHPS4 concentrations
,10-fold below IC50 concentrations during acute RHPS4
exposure (Figure 1).
(TIF)
Figure S2 Brain tumor cells can proliferate upon
RHPS4 removal. Brain tumor cells were exposed to RHPS4
for 72 hours prior to removal of drug and continued culture for a
further 48 hours in drug-free media. (A–B) PFSK-1 cells exhibit
recovery of cells after removal of media containing 0.5, 1.0 and
2.0 mM RHPS4 and continued proliferation, whereas DAOY, C6
and GB-1 cells exhibit recovery of cells and continued prolifer-
ation after removal of each RHPS4 concentration. Scale
bar = 25 mm.
(TIF)
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